tetano
Editor, Senior Moderator
Gen Hosp Psychiatry
. 2022 Feb 4;75:61-67.
doi: 10.1016/j.genhosppsych.2022.01.010. Online ahead of print.
Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression
Engelberta Pardamean[SUP] 1 [/SUP], Waskita Roan[SUP] 1 [/SUP], Karina Terry Amartini Iskandar[SUP] 2 [/SUP], Regina Prayangga[SUP] 2 [/SUP], Timotius Ivan Hariyanto[SUP] 3 [/SUP]
Affiliations
Abstract
Objective: Schizophrenia has been associated with patients' poor quality of life, disability, and hospitalization. As of today, evidence that highlights the association between schizophrenia and coronavirus disease (Covid-19) outcomes remains unclear. This study sought to analyze whether patients with pre-existing schizophrenia are at higher risk for Covid-19 mortality.
Methods: Using specific keywords, we comprehensively searched PubMed, Scopus, OVID, and Cochrane Library sources until November 15th, 2021. All published studies on schizophrenia and Covid-19 were collected. We used Review Manager 5.4 and Comprehensive Meta-Analysis 3 software to conduct statistical analysis.
Results: There were 10 studies with 263,207 Covid-19 patients included in the analysis. Evaluation of the data gathered yielded an association between schizophrenia and increased mortality from Covid-19 (RR 2.22; 95%CI: 1.54-3.20, p < 0.00001, I[SUP]2[/SUP] = 82% random-effect model). The increased risk of developing mortality from Covid-19 in patients with schizophrenia was significantly influenced by older age (p = 0.0004) and smoking (p = 0.0048).
Conclusions: This study proposes that patients with pre-existing schizophrenia are at risk of developing higher Covid-19 mortality. Patients with schizophrenia need special attention and should be prioritized to receive the SARS-CoV-2 vaccine. Registration details: CRD42021293997.
Keywords: Coronavirus disease 2019; Covid-19; Psychiatry; Psychosis; Schizophrenia.
. 2022 Feb 4;75:61-67.
doi: 10.1016/j.genhosppsych.2022.01.010. Online ahead of print.
Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression
Engelberta Pardamean[SUP] 1 [/SUP], Waskita Roan[SUP] 1 [/SUP], Karina Terry Amartini Iskandar[SUP] 2 [/SUP], Regina Prayangga[SUP] 2 [/SUP], Timotius Ivan Hariyanto[SUP] 3 [/SUP]
Affiliations
- PMID: 35182908
- DOI: 10.1016/j.genhosppsych.2022.01.010
Abstract
Objective: Schizophrenia has been associated with patients' poor quality of life, disability, and hospitalization. As of today, evidence that highlights the association between schizophrenia and coronavirus disease (Covid-19) outcomes remains unclear. This study sought to analyze whether patients with pre-existing schizophrenia are at higher risk for Covid-19 mortality.
Methods: Using specific keywords, we comprehensively searched PubMed, Scopus, OVID, and Cochrane Library sources until November 15th, 2021. All published studies on schizophrenia and Covid-19 were collected. We used Review Manager 5.4 and Comprehensive Meta-Analysis 3 software to conduct statistical analysis.
Results: There were 10 studies with 263,207 Covid-19 patients included in the analysis. Evaluation of the data gathered yielded an association between schizophrenia and increased mortality from Covid-19 (RR 2.22; 95%CI: 1.54-3.20, p < 0.00001, I[SUP]2[/SUP] = 82% random-effect model). The increased risk of developing mortality from Covid-19 in patients with schizophrenia was significantly influenced by older age (p = 0.0004) and smoking (p = 0.0048).
Conclusions: This study proposes that patients with pre-existing schizophrenia are at risk of developing higher Covid-19 mortality. Patients with schizophrenia need special attention and should be prioritized to receive the SARS-CoV-2 vaccine. Registration details: CRD42021293997.
Keywords: Coronavirus disease 2019; Covid-19; Psychiatry; Psychosis; Schizophrenia.